{"changes":[],"country":"US","description":"Scorpion Therapeutics is a clinical-stage precision-oncology biotech designing mutant-selective small molecules for patients with specific cancer driver mutations. It targets PI3K-alpha-mutant breast, gynecological, and other solid tumors. Lilly acquired the lead program STX-478 for up to $2.5B in milestones in early 2025.","domain":"scorpiontx.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech|oncology|therapeutics","investors":["lightspeed"],"lat":42.358834,"lng":-71.05783,"location":"Boston MA","name":"Scorpion Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":150000000,"currency":"USD","date":"2024-07-01","investors":["lightspeed"],"leadInvestor":"lightspeed","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"scorpiontx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"scorpiontx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://scorpiontx.com"},{"fact":"description","publisher":"scorpiontx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://scorpiontx.com"}],"stage":"series-b+","techStack":[],"totalRaisedUsd":150000000,"updatedAt":"2026-05-07"}